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Abstract
Background: Organic anion transporting polypeptide (OATP) 1B1, OATP1B3, and OATP2B1 (encoded by SLCO1B1,
SLCO1B3, SLCO2B1) mediate the hepatic uptake of endogenous compounds like bile acids and of drugs, for
example, the lipid-lowering atorvastatin, thereby influencing hepatobiliary elimination. Here we systematically
elucidated the contribution of SLCO variants on expression of the three hepatic OATPs under consideration of
additional important covariates.
Methods: Expression was quantified by RT-PCR and immunoblotting in 143 Caucasian liver samples. A total of 109 rare
and common variants in the SLCO1B3-SLCO1B1 genomic region and the SLCO2B1 gene were genotyped by MALDI-TOF
mass spectrometry and genome-wide SNP microarray technology. SLCO1B1 haplotypes affecting hepatic OATP1B1
expression were associated with pharmacokinetic data of the OATP1B1 substrate atorvastatin (n = 82).
Results: Expression of OATP1B1, OATP1B3, and OATP2B1 at the mRNA and protein levels showed marked
interindividual variability. All three OATPs were expressed in a coordinated fashion. By a multivariate regression
analysis adjusted for non-genetic and transcription covariates, increased OATP1B1 expression was associated with
the coding SLCO1B1 variant c.388A > G (rs2306283) even after correction for multiple testing (P = 0.00034). This
held true for haplotypes harboring c.388A > G but not the functional variant c.521T > C (rs4149056) associated
with statin-related myopathy. c.388A > G also significantly affected atorvastatin pharmacokinetics. SLCO variants
and non-genetic and regulatory covariates together accounted for 59% of variability of OATP1B1 expression.
Conclusions: Our results show that expression of OATP1B1, but not of OATP1B3 and OATP2B1, is significantly
affected by genetic variants. The SLCO1B1 variant c.388A > G is the major determinant with additional
consequences on atorvastatin plasma levels.
Background
The organic anion transporting polypeptides 1B1
(OATP1B1, encoded by the SLCO1B1 gene), OATP1B3
(SLCO1B3), and OATP2B1 (SLCO2B1) are major uptake
transporters on the sinusoidal membrane of human hepa-
tocytes. They mediate the influx of endogenous com-
pounds such as bile salts, bilirubin glucuronides, thyroid
hormones and steroid hormone metabolites, and clinically
frequently used drugs like statins, HIV protease inhibitors,
and the anti-cancer agents irinotecan or methotrexate
[1-5]. The importance of OATP transporters for hepato-
biliary uptake is emphasized by the Rotor syndrome,
which is a two-gene disorder caused by the complete com-
bined deficiency of OATP1B1 and OATP1B3 [6].
Numerous clinical studies support the relevance of com-
mon but also rare SLCO1B1 missense variants altering
either the pharmacokinetics or drug response of OATP1B1
substrates [4,7,8]. The common variant c.521T > C
(rs4149056; Val174Ala) is highlighted by a genome-wide
association study (GWAS) suggesting an increased risk for
simvastatin-induced myopathy in variant carriers [9].
Reduced hepatic uptake of the OATP1B1 substrates
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atorvastatin and rosuvastatin is supported by in vitro
experiments using cell lines stably expressing the c.521T >
C variant [2,10]. Moreover, the in vivo disposition of endo-
genous and/or xenobiotic substances, including drugs, is
also affected by SLCO1B3 and SLCO2B1 variants [11].
Irrespective of well-established data on functional conse-
quences of SLCO variants, the contribution of SLCO var-
iants to the interindividual variability of hepatic expression
of OATP transporters is still unknown. Although cholesta-
sis has been recognized as an additional determinant of
OATP1B1 and OATP1B3 expression [12], a comprehen-
sive analysis including SLCO variants as well as non-
genetic and regulatory covariates is presently lacking.
Similar to recent work related to the hepatic uptake trans-
porters OCT1 and OCT3 [13], we therefore investigated
the impact of > 100 SLCO variants as well as non-genetic
and regulatory covariates on the interindividual variability
of hepatic OATP1B1, OATP1B3, and OATP2B1 expres-
sion. The transcription factors hepatocyte nuclear factor
(HNF)1a, farnesoid X receptor (FXR), liver X receptor
(LXR)a, specificity protein 1 (Sp1), aryl hydrocarbon
receptor (AhR), constitutive androstane receptor (CAR),
and HNF3b were selected because literature data indicate
they are involved in regulation of the three hepatic SLCO
genes with potential consequences on variability of expres-
sion [14-21]. The novel finding that the SLCO1B1 mis-
sense variant Asn130Asp (rs2306283) alters hepatic
protein expression most effectively is supported by phar-
macokinetic data of atorvastatin in a study of healthy
volunteers. SLCO variants and non-genetic and regulatory
covariates accounted for 59% of variability of hepatic
OATP1B1 expression.
Materials and methods
Human liver samples
Liver tissue and corresponding blood samples were col-
lected from patients undergoing liver surgery at the
Department of General, Visceral, and Transplantation Sur-
gery (University Medical Center Charité, Berlin, Germany)
as described previously [13,22,23]. Tissue samples had
been examined by a pathologist; only histologically normal
liver tissue was used for further studies. For each patient,
detailed information was available regarding age, sex,
smoking status, alcohol consumption, presurgery medica-
tion, indication for liver resection, and presurgery liver
serum parameters. Samples from patients with hepatitis,
cirrhosis, or chronic alcohol use were excluded. A total of
143 liver samples from which high quality RNA and com-
plete documentation could be obtained were finally
included (Table S1 in Additional file 1). The study was
approved by the ethics committees of the Charité, Hum-
boldt University (Berlin, Germany) and the University of
Tübingen (Tübingen, Germany) in accordance with the
principles of the Declaration of Helsinki. Written informed
consent was obtained from each patient.
Atorvastatin pharmacokinetics in vivo
Atorvastatin pharmacokinetic variables were obtained
from 82 healthy volunteers (Table S2 in Additional file 1)
as previously described [24-26]. Briefly, volunteers ingested
a single 20 mg dose of atorvastatin (Lipitor; Pfizer/Göd-
ecke, Karlsruhe, Germany). No other drugs or grapefruit
products were consumed prior to atorvastatin administra-
tion [25]. The study was approved by the Ethics Commit-
tee of the Hospital District of Helsinki and Uusimaa,
Finland. Written informed consent was obtained from the
participants.
Selection of genetic variants and genotyping strategies
Genomic DNA was purified from EDTA blood samples
with the QIAmp DNA Blood MiniKit (Qiagen, Hilden, Ger-
many). All samples were genotyped for 109 genetic variants
(Figure S1 and Table S3 in Additional file 1). We selected
58 genetic variants of the SLCO1B3-SLCO1B1 genomic
region (chromosome 12) and the SLCO2B1 gene (chromo-
some 11) from the National Center for Biotechnology Infor-
mation database (dbSNP build 129) based on functional
criteria and/or frequency distribution. Genotyping was per-
formed by matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry (MALDI-TOF MS) using the
MassARRAY Compact system (Sequenom, San Diego, CA,
USA) or by 5’-nuclease assays (ABI Prism 7900 Sequence
Detection System, Applied Biosystems/Life Technologies,
Carlsbad, CA, USA). Moreover, 51 additional variants of the
SLCO1B3-SLCO1B1 genomic region and the SLCO2B1
gene were genotyped using the HumanHap300v1.1 chip
data set (Illumina, San Diego, CA, USA) as described pre-
viously [27] (NCBI Gene Expression Omnibus series
GSE39036, GSE32504). For MALDI-TOF MS and TaqMan
analysis, about 10% of samples were re-genotyped as quality
control resulting in 100% concordance. Missing calls in
MALDI-TOF MS and TaqMan genotyping were re-typed,
resulting in final call rates of 99%. Laboratory staff were
blinded to the case status of liver samples. Details of primers
and genotyping assays are available upon request.
RNA isolation and quantification
High-quality total RNA was extracted from liver samples
and reverse-transcribed as described [13]. mRNA was
quantified by TaqMan technology (Additional file 1).
Quantification of OATPs in human liver samples
OATP proteins were quantified in membrane fractions
from the liver samples by immunoblot analyses using
previously characterized antibodies [28,29] (Additional
file 1).
Nies et al. Genome Medicine 2013, 5:1
http://genomemedicine.com/content/5/1/1
Page 2 of 11
Generation of HEK cells stably expressing OATP2B1 and
missense variants
Human embryonic kidney (HEK) cells were transfected
with constructs encoding human SLCO2B1 or the missense
variants c.601G > A (rs35199625; GenBank: NM_007256.4
as reference), c.935G > A (rs12422149), and c.1457C > T
(rs2306168) (Additional file 1).
Immunofluorescence microscopy
Cryosections of liver samples were immunostained for
OATP1B1 and OATP2B1 using previously characterized
antibodies [29,30]. Images were taken with a confocal
laser scanning microscope (Additional file 1).
Transport studies and prediction of functional effects
Transport of atorvastatin, rosuvastatin, and estrone sulfate
by OATP2B1 and variants was measured using stably-
transfected HEK cells (Additional file 1). Functional effects
of OATP2B1 missense variants were calculated using four
different algorithms (Additional file 1).
Statistics
Hardy-Weinberg equilibrium calculations [31,32] were used
to compare observed and expected allele and genotype fre-
quencies. Linkage disequilibrium analysis of the SLCO1B3-
SLCO1B1 genomic region and the SLCO2B1 gene was per-
formed with Haploview [31] using results from our study
population of 143 Caucasians. Haplotype analysis was per-
formed with R-package haplo.stats-1.4.4 [33] (R-2.13.0).
R-Package SNPassoc-1.6-0 was applied to study associa-
tions between each variant and OATP expression, with
correction for non-genetic (Table 1) and transcription fac-
tors (HNF1a, Sp1, AhR, LXRa, FXR, CAR, HNF3b). Mul-
tivariate linear models and step-wise model selection were
used to determine the fraction of variance in OATP
expression explained by non-genetic, genetic, and tran-
scription covariates. All statistical tests were two-tailed
and statistical significance was defined as P < 0.05. Where
indicated, P-values were adjusted for multiple testing
according to Holm [34] (see Additional file 1 for detailed
information).
Results
Hepatic OATP expression
OATP1B1, OATP1B3, and OATP2B1 mRNA and pro-
tein expression varied considerably within the 143 liver
samples and were not normally distributed (Figure 1; Fig-
ure S2 in Additional file 1). mRNA and protein expression
weakly correlated for SLCO1B1/OATP1B1 and SLCO1B3/
OATP1B3, but not for SLCO2B1/OATP2B1 (Figure 1b-d).
Marked interindividual variability was also obtained when
only non-cholestatic liver samples (n = 117) were analyzed
(Table S4A in Additional file 1). Moreover, of interest,
SLCO1B1, SLCO1B3, and SLCO2B1 mRNA levels were
significantly correlated with each other, which held true to
a lesser extent for protein levels (Figure 1e, f).
Impact of non-genetic factors on OATP expression
Multivariate linear regression analyses showed no asso-
ciation between OATP expression and sex, age, smoking
habit, presurgery medication, bilirubin levels, or g-gluta-
myl transferase levels (Table 1). Alcohol consumption
was significantly associated with reduced SLCO1B1 and
SLCO2B1 mRNA levels. Pathophysiologically increased
C-reactive protein levels were associated with reduced
SLCO1B1 mRNA levels. As expected from previous stu-
dies [12], OATP1B1 and OATP1B3 protein levels were
significantly lower in cholestatic liver samples. When
analyzing only the non-cholestatic samples, alcohol con-
sumption was again significantly associated with reduced
SLCO2B1 mRNA levels (Table S5 in Additional file 1).
SLCO genetic variants and frequencies
Table S3 in Additional file 1 specifies all 109 common and
rare variants genotyped, including additional information
on location and allele frequencies. We detected 83 variants
in the 143 liver samples, 66 variants in the SLCO1B3-
SLCO1B1 genomic region and 17 variants in the SLCO2B1
gene (Figure S1 in Additional file 1). No deviations from
Hardy-Weinberg equilibrium were observed. Notably,
nearly complete linkage disequilibrium was observed for
several variants in SLCO1B1 (Figure 2a).
SLCO/OATP genotype-phenotype correlation analyses
In order to exclude confounding by cholestasis, all subse-
quent analyses were performed with the non-cholestatic
liver samples (n = 117). Multivariate linear regression
models were used to analyze associations between variants
with frequencies ≥ 1% in the SLCO1B3-SLCO1B1 genomic
region and the SLCO2B1 gene (Figure S1 in Additional
file 1) and the expression of OATP1B1, OATP1B3, and
OATP2B1. Models were corrected for eight non-genetic
covariates (Table S6 in Additional file 1) and the regula-
tory factors HNF1, LXR, FXR, HNF3, Sp1, CAR, and AhR
previously suggested by literature data as transcriptional
regulators of at least one SLCO gene [14-21]. Interindivi-
dual variability of the expression of these transcription fac-
tors is given in Table S4B in Additional file 1.
Considering the additive genetic model, 38 variants in
the SLCO1B3-SLCO1B1 genomic region correlated with
OATP1B1 or OATP1B3 expression, and 3 variants in the
SLCO2B1 gene with OATP2B1 expression (Table S6 in
Additional file 1). After multiple testing correction, 16 var-
iants in the SLCO1B3-SLCO1B1 genomic region were
still significantly associated with OATP1B1 expression.
Notably, for the OATP1B1 protein, variant c.388A > G
(Asn130Asp, rs2306283) showed the lowest P-value (P =
0.00034) whereas the variant c.521T > C (Val174Ala,
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rs4149056), associated with statin-induced myopathy
[9,35,36], did not show any association. Stratification of
baseline characteristics by carriers of c.388A > G (domi-
nant model) did not show any significance.
Additionally, we calculated haplotypes for the non-cho-
lestatic liver samples using different strategies. Firstly, hap-
lotypes were calculated for genetic variants of SLCO1B1,
SLCO1B3, and SLCO2B1 detected in the liver samples
(Table S3 in Additional file 1). Only variants with a fre-
quency ≥ 1% were included. Significant associations with
substantial effect sizes between haplotypes and expression
were only found for OATP1B1 protein and SLCO2B1
mRNA expression, even after correction for multiple test-
ing (Tables S7 to S9 in Additional file 1). Secondly, pre-
viously reported SLCO1B1 haplotypes containing only the
variants c.388A > G, c.463C > A, c.521T > C and c.1929A
> C were calculated (Figure 2c). The haplotypes *1b (P =
0.0037), *14 (P = 1.8 × 10-5), and *35 (P = 0.0004), includ-
ing the c.388A > G but not the c.521T > C variant, were
significantly associated with increased OATP1B1 protein
expression, even after multiple testing correction. These
haplotypes exhibited substantial effect sizes (*1b, 0.43; *14,
0.53; *35, 0.56) and clustered with samples of highest med-
ian OATP1B1 expression (Figure 2d). OATP1B1 protein
levels also increased with the number of *1b, *14, and *35
alleles (Figure S3A in Additional file 1).
Thirdly, we calculated haplotypes covering all variants of
the SLCO1B3-SLCO1B1 genomic region (Table S10 in
Additional file 1). Two haplotypes, which included the
SLCO1B1 variant c.388A > G, were significantly associated
with increased OATP1B1 protein levels and showed sub-
stantial effect sizes for the correlation (H-cluster04, 0.62; H-
cluster12, 0.59).
Contribution of genetic, non-genetic, and transcription
factors to variable OATP expression
Interindividual variability of hepatic OATP1B1 protein
expression was substantially explained by SLCO1B1
variants (50%) while non-genetic (8%) and transcription
factors (7%) contributed only to a minor extent (Figure
2e). Notably, 59% of variability could be apportioned to
the combination of all three categories (that is, genetic,
non-genetic, transcription factors). Total variance of
OATP1B3 protein expression was explained to 55% by
these categories but only 24% of variance of OATP2B1
protein expression could be apportioned to the three
categories.
Atorvastatin pharmacokinetics
SLCO1B1 haplotypes for all 82 volunteers were calculated
considering the SLCO1B1 variants c.388A > G, c.463C >
A, c.521T > C and c.1929A > C. Seven different haplotypes
with a frequency distribution ≥ 2% were detected
(Figure 3a; Table S11 in Additional file 1). A linear regres-
sion analysis including body weight as covariate indicated
that the haplotypes *1b and *14, both harboring c.388A >
G but not c.521T > C, were associated with decreased
atorvastatin area under the plasma concentration-time
curve (AUC) compared to the reference haplotype (*1a),
reaching statistical significance for *14 (P = 0.0126).
Notably, homozygous carriers of *1b and *14 showed the
lowest atorvastatin AUC (Figure 3b). In contrast, haplo-
type *15, harboring c.388A > G and c.521T > C, was asso-
ciated with an increased atorvastatin AUC (P = 2.7 × 10-6;
Figure 3a) and an increased atorvastatin Cmax (P = 0.031;
Table S11 in Additional file 1). Here, homozygous carriers
for *15 showed highest AUC for the total study cohort
(Figure 3b). Atorvastatin AUC also decreased with the
number of *1b and *14 alleles (Figure S3B in Additional
file 1).
In order to identify whether the effects of variant c.388A
> G may be confounded by variant c.521T > C, we con-
ducted multivariate models including both variants simul-
taneously. The variant c.388A > G was significantly
associated with decreased AUC for atorvastatin (P =
0.00066, recessive model) whereas the variant c.521T > C
Table 1 Multivariate analysis of hepatic OATP expression in relation to 10 non-genetic factors in the total sample set
of 143 human livers
P-value
Non-genetic factor SLCO1B1 mRNA OATP1B1 protein SLCO1B3 mRNA OATP1B3 protein SLCO2B1 mRNA OATP2B1 protein
Sex 0.903 0.766 0.661 0.463 0.623 0.072
Age 0.502 0.630 0.466 0.060 0.711 0.947
Smoking habit 0.534 0.454 0.173 0.731 0.214 0.278
Alcohol consumption 0.037 0.124 0.076 0.904 0.001 0.206
Pre-surgery drugs 0.294 0.786 0.638 0.401 0.567 0.168
Diagnosis 0.458 0.046 0.238 0.101 0.506 0.066
Bilirubin 0.846 0.108 0.348 0.194 0.997 0.847
g-Glutamyl transferase 0.363 0.820 0.548 0.448 0.461 0.547
Cholestasis 0.286 0.020 0.008 0.021 0.467 0.232
C-reactive protein 0.039 0.070 0.873 0.132 0.520 0.466
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Figure 1 Hepatic expression of OATP1B1, OATP1B3 and OATP2B1 varies between individuals, but is coordinately regulated within one
individual. (a) Representative immunoblot of liver membrane fractions (20 μg) quantified relative to a standard liver sample. (b-d) Correlation
analyses of OATP protein and SLCO mRNA levels in human liver samples. (e, f) Correlation analyses of all three OATPs showed a coordinated
expression of SLCO1B1, SLCO1B3, and SLCO2B1 mRNA and OATP1B1, OATP1B3, and OATP2B1 protein levels in the non-cholestatic liver sample
set. rS, Spearman rank-order correlation coefficient.
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Figure 2 SLCO genetic variants affect expression of hepatic OATPs. (a, b) Pairwise linkage disequilibrium map of the SLCO1B3-SLCO1B1
genomic region (a) and the SLCO2B1 gene (b) including all variants detected in the 143 livers. Coloring corresponds to the standard Haploview
(D’/LOD) [31]. (c,d) SLCO1B1 haplotypes, calculated based on the four missense variants present in the liver cohort (c.388A > G, c.463C > A,
c.521T > C, c.1929A > C) and also previously described as key variants [8,80], affect OATP1B1 protein expression in the non-cholestatic liver
samples (n = 117). Only haplotypes with frequencies ≥ 2% are given. The effect sizes indicate differences of OATP1B1 expression compared to
reference haplotype SLCO1B1*1a. Boldface: significant P-values. (d) SLCO1B1 genotypes (percentage genotype frequencies in brackets) are sorted
by median OATP1B1 protein expression. SLCO1B1 alleles harboring only variant c.388A > G and not c.521T > C (*1b, *14, *35, boldface) confer
considerably higher OATP1B1 expression in a gene-dose dependent manner. Horizontal line indicates median; boxes indicate the 25th to 75th
percentiles; whiskers indicate non-outlier range. (e) Percentage of interindividual variability of expression of OATPs in the non-cholestatic liver
samples apportioned to non-genetic factors (gray), regulatory factors (blue), and SLCO variants (orange), and to the combination of all three
categories (red) was calculated using multivariate linear regression analyses and stepwise model selection.
Nies et al. Genome Medicine 2013, 5:1
http://genomemedicine.com/content/5/1/1
Page 6 of 11
resulted in an increased AUC (P = 2.6 × 10-10, additive
model). Of note, these data held true when the interaction
effect of c.388A > G and c.521T > C was included into the
model (c.388A > G, P = 0.00535; c.521T > C, P = 3.0 ×
10-7; interaction effect, P = 0.67).
Statin transport by OATP2B1 and its missense variants
The SLCO2B1 missense variants c.601G > A, c.935G > A
and c.1457C > T were the only ones present in our liver
cohort (Table S3 in Additional file 1). Although they had
no effect on expression (Figure 2e), functional conse-
quences of these variants could not be excluded with cer-
tainty. We therefore stably expressed the three variants
separately in HEK cells. The variant transfectants showed
correct immunolocalization of OATP2B1 in the plasma
membrane (Figure S4A in Additional file 1). Only c.1457C
> T but not c.601G > A or c.935G > A showed reduced
uptake of atorvastatin, rosuvastatin and the prototypical
substrate estrone sulfate (Figure S5 in Additional file 1).
The calculated maximal uptake rate of atorvastatin was sig-
nificantly lower for c.1457C > T and tended to be lower for
rosuvastatin (Table S12 in Additional file 1). In contrast,
the Km value of c.935G > A was significantly higher for
atorvastatin (Table S12 in Additional file 1). Sinusoidal
hepatocyte membrane immunostaining of OATP2B1 in
liver cryosections from homozygous variant carriers for
c.935AA was similar to OATP2B1-reference (Figure S4B in
Additional file 1). Moreover, four independent computa-
tional tools did not correctly predict experimental uptake
data (Table S13 in Additional file 1). Altogether, the uptake
studies indicate some functional consequences, which
needs validation by in vivo studies.
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c.521T > C (boldface) confer considerably lower AUCs with lowest levels in homozygous variant or compound heterozygous carriers for the
SLCO1B1*14 or *1b alleles. Horizontal line indicates the median; boxes indicate 25th to 75th percentiles; whiskers indicate non-outlier range.
Nies et al. Genome Medicine 2013, 5:1
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Discussion
This first systematic analysis of the human membrane
transporters OATP1B1, OATP1B3, and OATP2B1 on
the interindividual variability of hepatic expression
revealed a major contribution of SLCO1B1 variants on
OATP1B1 protein expression. Expression of OATP1B3
or OATP2B1 was apparently not influenced by genetic
variants. Most strikingly, the SLCO1B1 missense variant
c.388A > G resulted in the strongest association with
increased OATP1B1 protein expression whereas the
c.521T > C variant, linked to statin-related myopathy
[9,35,36], did not alter protein levels. This was observed
for both the non-cholestatic livers (n = 117; Figure 2c, d)
as well as the total liver set of 143 samples (Table S14 in
Additional file 1), indicating that c.388A > G alters
OATP1B1 expression independent of cholestasis. The
observation that variant c.388A > G is associated with
highest OATP1B1 protein expression is corroborated by
our haplotype analysis since homozygous or compound
heterozygous carriers of haplotypes *1b, *14, or *35, har-
boring c.388A > G but not c.521T > C, showed also the
highest OATP1B1 protein levels. A mislocalization of
OATP1B1 protein in genotyped livers for variant c.388A
> G could be excluded by immunolocalization analyses
(Figure S6 in Additional file 1).
The results of the liver study are confirmed by func-
tional data of the pharmacokinetic healthy volunteer
study since the *14 haplotype was associated with a sig-
nificantly decreased atorvastatin plasma AUC in contrast
to the *15 haplotype, harboring both c.388A > G and
c.521T > C, and resulting in an increased AUC. Thus, the
SLCO1B1 variant c.388A > G is an important determi-
nant of OATP1B1 expression and function, independent
of the c.521T > C variant. In line with in vitro reports
[37,38], one may suggest that the increased clearance by
OATP1B1 c.388A > G is mainly caused by a higher pro-
tein expression. The increased hepatic atorvastatin
uptake in c.388A > G carriers is also supported by haplo-
type data from previous studies indicating that only
c.388A > G was associated with significant lower AUCs
for the OATP1B1 substrates pravastatin and repaglinide
[39-41]. Moreover, variant c.388A > G carriers showed a
significantly improved response to statins measured by
low-density lipoprotein cholesterol levels [42,43] and
were even protected from statin-induced side effects [42].
Of note, however, the effect of the c.388A > G variant
seems to be substrate-specific since the AUC was not
altered, for example, for rosuvastatin [44], underscoring
the requirement to perform pharmacokinetic studies for
each OATP1B1 drug separately. Mechanistically, we sug-
gest that variant c.388A > G modifies mRNA secondary
structure, resulting in an alteration of translation effi-
ciency as previously shown for the CFTR membrane
protein [45]. Indeed, computational theoretical modeling
provided evidence that the SLCO1B1 mRNA secondary
structures are altered only by haplotypes *1b, *14, and
*35 harboring the c.388A > G variant (Figure S7 in Addi-
tional file 1).
In line with the localization of the OATP1B1*15 protein in
the cell membrane using stably expressing HEK cells [38], a
mislocalization of the OATP1B1 protein in livers genotyped
for *15 haplotype was not found. The increased atorvastatin
AUC in carriers of the *15 haplotype in our pharmacokinetic
study revealed impaired atorvastatin uptake, indicating that
the variant OATP1B1*15 protein is associated with
decreased intrinsic transport activity. This observation is
supported by previous studies using oocytes that revealed
significantly reduced atorvastatin uptake by OATP1B1*15 in
comparison with the reference sequence [46].
Another novel observation of our study is the coordi-
nated expression of OATP1B1, OATP1B3, and OATP2B1
in human liver. The coordinate expression may be
explained by regulatory networks considering previously
identified transcription factors like HNF1a, Sp1, AhR,
LXRa, FXR, CAR, and HNF3b [14-21]. Since HNF1a con-
fers basal promoter activity of SLCO1B1 and SLCO1B3
and functional binding sites have been detected in the pro-
moter regions of both genes [14,17], we analyzed the
impact of HNF1a on SLCO mRNA expression. Because
exon_1e transcripts of SLCO2B1 are highly abundant in
human liver [47] and the exon_1e promoter region has so
far not been analyzed, we identified three high-scoring
putative HNF1a binding sites in the exon_1e promoter
(Methods and Figure S8A in Additional file 1) by in silico
analysis. Electromobility shift assays confirmed in vitro
binding of HNF1a to each of the three identified motifs,
thereby indicating that the exon_1e transcript of SLCO2B1
is regulated by HNF1a in liver. Binding of HNF1a to any
of the three sites in the exon_1e promoter of SLCO2B1
appeared to be weaker than binding to the respective
motifs in the SLCO1B1 and SLCO1B3 gene promoters
(Figure S8B in Additional file 1).
Among several clinical and demographic factors,
including age, sex, alcohol consumption, smoking habit,
and presurgery medication, only cholestasis resulted in
significantly reduced OATP1B1 and OATP1B3 protein
levels considering the total set of 143 liver samples
(Table 1). This is in line with previous data since choles-
tasis in cases of primary biliary cirrhosis or progressive
familial intrahepatic cholestasis is associated with
reduced OATP1B1 and OATP1B3 expression [12] and
the concerted down-regulation of both bile salt uptake
transporters is considered as a protective mechanism
against hepatocellular injury caused by cytotoxic bile
acids. Cholestasis-related down-regulation of OATP1B1
and OATP1B3 might be of clinical relevance regarding
Nies et al. Genome Medicine 2013, 5:1
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drug response to several well-established OATP sub-
strates, for example, lopinavir [48] and irinotecan [49].
Moreover, one aim of our study was to elucidate sys-
tematically the contribution of genetic, non-genetic and
regulatory factors for the prediction of the interindividual
variability of the expression of hepatic OATP transpor-
ters. Generally, the interindividual variability of expres-
sion of hepatic OATPs is considerably higher than
variation of the hepatic intrinsic clearance of drugs that
are substrates for OATP transport proteins as reported
by clinical studies [50]. This discrepancy is, however, not
surprising since the hepatic clearance is the sum of a
number of processes and factors - for example, involve-
ment of different drug transporters for one substrate
drug, short-term regulation of transporters (for example,
by protein kinases), differences in retrieval of transporters
from the plasma membrane, and multiple binding sites
on transporters. Our multivariate analyses only using
non-cholestatic liver samples revealed that the combina-
tion of genetic, non-genetic, and transcription factors
explained 59% and 55% of variability of OATP1B1 and
OATP1B3 protein expression, respectively, while
OATP2B1 protein variance remained largely unaffected
(24%). Several reasons might explain the poor prediction
of interindividual variability of hepatic OATP2B1 expres-
sion, although systematic ascertainment of covariates in
our liver bank was guaranteed [51] (Table S1 in Addi-
tional file 1). Other non-genetic factors like cytokines
[52] may affect OATP2B1 expression. Moreover, uniden-
tified transcription factors, genetic variation in those
genes as well as epigenetics such as DNA methylation
[53] or regulation by microRNA [54] may contribute to
the interindividual variability of OATP2B1.
Conclusions
In our comprehensive work on the expression of hepatic
OATPs we show for the first time a major contribution of
SLCO1B1 genetics to the interindividual variability of
OATP1B1 protein expression. The SLCO1B1 variant
c.388A > G strongly affects OATP1B1 expression with
additional functional consequences on atorvastatin plasma
levels. Further work is warranted to identify underlying
mechanisms for the so far unexplained interindividual
variability of hepatic OATP1B3 and OATP2B1 expression.
Additional material
Additional data file 1: Additional methods, tables and figures [55-
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